Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Hold” from Brokerages

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has received a consensus recommendation of “Hold” from the thirteen brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $19.7273.

BCYC has been the topic of a number of recent research reports. Citizens Jmp upped their price target on Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a research report on Friday, October 31st. Truist Financial initiated coverage on shares of Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday. JMP Securities set a $12.00 target price on Bicycle Therapeutics in a research report on Friday, October 31st. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $11.00 price target (down from $27.00) on shares of Bicycle Therapeutics in a research report on Friday, October 31st.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the sale, the chief executive officer directly owned 475,310 shares of the company’s stock, valued at approximately $3,997,357.10. This represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 8,527 shares of company stock worth $71,738 in the last quarter. Corporate insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BCYC. Long Focus Capital Management LLC boosted its position in shares of Bicycle Therapeutics by 138.2% during the 1st quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company’s stock valued at $10,984,000 after acquiring an additional 750,661 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Bicycle Therapeutics by 454.1% in the 2nd quarter. Acadian Asset Management LLC now owns 698,501 shares of the company’s stock worth $4,840,000 after acquiring an additional 572,439 shares in the last quarter. Armistice Capital LLC lifted its position in Bicycle Therapeutics by 21.7% during the 1st quarter. Armistice Capital LLC now owns 2,672,000 shares of the company’s stock valued at $22,685,000 after acquiring an additional 476,000 shares during the period. Principal Financial Group Inc. boosted its stake in Bicycle Therapeutics by 64.7% during the third quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock worth $8,889,000 after acquiring an additional 451,135 shares in the last quarter. Finally, Tybourne Capital Management HK Ltd. grew its holdings in Bicycle Therapeutics by 72.4% in the second quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock worth $6,907,000 after purchasing an additional 417,400 shares during the period. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Stock Up 0.6%

BCYC opened at $6.99 on Friday. Bicycle Therapeutics has a twelve month low of $6.03 and a twelve month high of $15.47. The company’s 50-day moving average price is $7.17 and its two-hundred day moving average price is $7.50. The stock has a market cap of $484.55 million, a price-to-earnings ratio of -1.93 and a beta of 1.47.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.24. Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. The company had revenue of $11.73 million for the quarter, compared to analysts’ expectations of $8.25 million. As a group, sell-side analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.